Erythropoietin Reduces the Degree of Arthritis Caused by Type II Collagen in the Mouse

被引:47
作者
Cuzzocrea, Salvatore [1 ]
Mazzon, Emanuela
di Paola, Rosanna
Genovese, Tiziana
Patel, Nimesh S. A. [2 ]
Britti, Domenico [3 ]
de Majo, Massimo
Caputi, Achille P.
Thiemermann, Christoph [2 ]
机构
[1] Univ Messina, Inst Pharmacol, Sch Med, I-98100 Messina, Italy
[2] St Bartholomews & Royal London Sch Med & Dent, William Harvey Res Inst, London, England
[3] Univ Teramo, Teramo, Italy
来源
ARTHRITIS AND RHEUMATISM | 2005年 / 52卷 / 03期
关键词
D O I
10.1002/art.20875
中图分类号
R5 [内科学];
学科分类号
1002 [临床医学]; 100201 [内科学];
摘要
Objective. Erythropoietin (EPO) is a potent stimulator of erythroid progenitor cells, and its expression is enhanced by hypoxia. The aim of this study was to investigate the effect of EPO on collagen-induced arthritis (CIA) in the mouse. Methods. CIA was induced by intradermal injection of bovine type 11 collagen (CII) and Freund's complete adjuvant. Starting on day 25, some of the mice with CIA received daily subcutaneous injections of EPO (1,000 units/kg). Two other groups of mice received sham treatment alone or sham treatment followed by EPO treatment, respectively. Arthritis was assessed clinically, radiologically, and histologically. Cytokine and chemokine levels were measured, and neutrophil infiltration into inflamed joints was quantitated. Immunohistochemistry studies were performed to measure protein nitrosylation. Chondrocyte apoptosis was assessed by TUNEL assay. Results. Macroscopic clinical evidence of CIA first appeared as periarticular erythema and edema in the hind paws. The incidence of CIA was 100% by day 27 in the CII-challenged mice, and the severity of CIA progressed over a 35-day period, with radiographic evaluation revealing focal resorption of bone. Histopathologic features of CIA included erosion of the cartilage at the joint margins. Treatment with EPO starting at the onset of arthritis (day 25) ameliorated the clinical signs on days 26-35 and improved histologic status in the joints and paws. The degree of oxidative and nitrosative damage was significantly reduced in EPO-treated mice as indicated by decreased nitrotyrosine formation and poly (ADP-ribose) polymerase activation. Plasma levels of the proinflammatory cytokine tumor necrosis factor a were also significantly reduced by EPO treatment. In addition, EPO reduced the levels of apoptosis in chondrocytes in articular cartilage, as indicated by decreased TUNEL staining. Conclusion. These findings demonstrate that EPO exerts an antiinflammatory effect during chronic inflammation and is able to ameliorate the tissue damage associated with CIA.
引用
收藏
页码:940 / 950
页数:11
相关论文
共 53 条
[1]
Erythropoietin attenuates the tissue injury associated with hemorrhagic shock and myocardial ischemia [J].
Abdelrahman, M ;
Sharples, EJ ;
McDonald, MC ;
Collin, M ;
Patel, NSA ;
Yaqoob, MM ;
Thiemermann, C .
SHOCK, 2004, 22 (01) :63-69
[2]
Akisu M, 2001, ACTA MED OKAYAMA, V55, P357
[3]
Normobaric hypoxia induces tolerance to focal permanent cerebral ischemia in association with an increased expression of hypoxia-inducible factor-1 and its target genes, erythropoietin and VEGF, in the adult mouse brain [J].
Bernaudin, M ;
Nedelec, AS ;
Divoux, D ;
MacKenzie, ET ;
Petit, E ;
Schumann-Bard, P .
JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM, 2002, 22 (04) :393-403
[4]
Bresnihan B, 1998, ARTHRITIS RHEUM, V41, P2196, DOI 10.1002/1529-0131(199812)41:12<2196::AID-ART15>3.0.CO
[5]
2-2
[6]
Erythropoietin crosses the blood-brain barrier to protect against experimental brain injury [J].
Brines, ML ;
Ghezzi, P ;
Keenan, S ;
Agnello, D ;
de Lanerolle, NC ;
Cerami, C ;
Itri, LM ;
Cerami, A .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2000, 97 (19) :10526-10531
[7]
ANEMIA OF INFECTION .20. KINETICS OF IRON METABOLISM IN THE ANEMIA ASSOCIATED WITH CHRONIC INFECTION [J].
BUSH, JA ;
ASHENBRUCKER, H ;
CARTWRIGHT, GE ;
WINTROBE, MM .
JOURNAL OF CLINICAL INVESTIGATION, 1956, 35 (01) :89-97
[8]
Campbell IK, 2000, EUR J IMMUNOL, V30, P1568, DOI 10.1002/1521-4141(200006)30:6<1568::AID-IMMU1568>3.0.CO
[9]
2-R
[10]
The phosphoinositide 3-kinase pathway [J].
Cantley, LC .
SCIENCE, 2002, 296 (5573) :1655-1657